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ABSTRACT 
 
 
Depression is the leading cause of disability among women of reproductive age 
worldwide. Upwards of 1 in 5 women suffer from perinatal depression. This condition has 
deleterious effects on several birth outcomes, infant attachment, and children’s 
behavior/development. Maternal suicide causes 20% of postpartum deaths in depressed 
women.  Although the vast majority of perinatal women are amenable to being screened 
for depression, screening alone does not improve treatment rates or patient outcomes. 
Obstetrics/Gynecology (Ob/Gyn) clinics need supports in place to adequately address 
depression in their patient populations. The primary goal of this thesis is to develop, 
refine, and pilot test a new low-cost and sustainable stepped care program for Ob/Gyn 
clinics that will improve perinatal women’s depression treatment rates and outcomes. 
We developed and beta tested the Rapid Access to Perinatal Psychiatric Care in 
Depression (RAPPID) Program, to create a comprehensive intervention that is proactive, 
multifaceted, and practical. RAPPID aims to improve perinatal depression treatment and 
treatment response rates through: (1) access to immediate resource provision/referrals 
and psychiatric telephone consultation for Ob/Gyn providers; (2) clinic-specific 
implementation of depression care, including training support and toolkits; and (3) 
proactive depression screening, assessment, and treatment in OB/Gyn clinics. RAPPID 
builds on a low-cost and widely disseminated population-based model for delivering 
psychiatric care in primary care settings. Formative data and feedback from key 
stakeholders also informed the development of RAPPID.  Our formative and pilot work in 
real-world settings suggests RAPPID is feasible and has the potential to improve 
depression detection and treatment in Ob/Gyn settings. The next step will be to compare 
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two active interventions, RAPPID vs. enhanced usual care (access to resource 
provision/referrals and psychiatric telephone consultation) in a cluster-randomized trial in 
which we will randomize 12 Ob/Gyn clinics to either RAPPID or enhanced usual care.  
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PREFACE 
 Perinatal depression, which is a Major Depressive Disorder occurring 
during pregnancy or within one year of delivery, is a widespread problem, which 
in turn, may complicate birth,1 infant,2 and child outcomes.3-5 While upwards of 
one quarter of ethnically diverse women suffer from perinatal depression,6,7 the 
vast majority go untreated.8-11 Depression in pregnancy has deleterious effects 
on obstetric and birth outcomes including  preeclampsia, preterm birth, low birth 
weight,1,12 elective termination of pregnancy,13 alcohol/tobacco abuse,14 and 
postpartum depression.15 Postpartum depression  is associated with attachment 
insecurity,3 difficult infant/childhood temperament,3,16 and long-term 
consequences in children, including developmental delay, impaired language 
development4,5 and depressive, anxiety or disruptive disorders.17  These negative 
outcomes can be mitigated by leveraging existing resources to bring effective 
treatment for depression to women receiving care in obstetric settings.  
 Perinatal depression is increasingly recognized as a major public health 
problem.  Despite the profound negative effects on mother and children, which 
are mitigated by effective treatment18 including psychopharmacology and 
psychotherapy,19 perinatal depression remains under-diagnosed.8-10,20 
Acknowledging this lack of detection, several states have mandated screening 
for postpartum depression.21,22 In 2010 the Massachusetts (MA) state legislature  
created a Special Legislative Commission on Postpartum Depression to consider 
relevant current research and to recommend screening and treatment policies.23  
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The American College of Obstetricians and Gynecologists24,25 and other 
stakeholders26-30 recommend strong consideration by obstetricians for 
depression screening, noting potential benefits to women and their families. 
Screening for depression is highly accepted by perinatal women and Ob/Gyn 
providers.31,32  However, most efforts to screen have only focused on postpartum 
depression, which does not detect the 60% of postpartum depression that begins 
before or during pregnancy.33  For these reasons, the RAPPID program focuses 
on the entire relevant perinatal period, rather than just the postpartum period. 
 Screening for perinatal depression alone does not translate into treatment 
participation because women and obstetric providers experience multi-level 
barriers. Perinatal women and their obstetric providers find screening for 
perinatal depression a futile exercise when done in the absence of trained 
providers with access to mental health resources and referrals.  In our formative 
studies,34-37 and  our literature review,38 we identified a number of patient, 
provider, and systems-level barriers and facilitators to the treatment of perinatal 
depression and reviewed clinical, programmatic, and systems-level interventions. 
Provider and systems-level barriers identified included: (1) lack of obstetric 
provider training in technical aspects of depression care38-40 and communication 
skills in this context;41 (2) absence of standardized processes and procedures for 
stepped depression care;39,40 (3) lack of mental health providers willingness  to 
treat pregnant women;40 (4) lack of referral networks;39-43 and (5) inadequate 
capacity for follow-up and care coordination.39-43 These barriers are exacerbated 
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by patient-level barriers. Perinatal women report that they are afraid to disclose 
mental health concerns due to fears of stigma, losing parental rights, and being 
judged as an unfit mother.44-63 Many women perceive obstetric providers and 
staff as unsupportive, unavailable,47,49,50,57,58,61,64-66 and inadequately trained in 
depression assessment and treatment.64,65  The RAPPID program aims to 
address these critical barriers at the provider, patient, and system level. 
 Obstetric clinics/practices need supports in place to adequately address 
depression in their patient populations.32 Despite high acceptance of depression 
screening by perinatal women, many are not amenable to contact with a mental 
health provider.8-10,11 Less than 30%  of women who screen positive for 
depression attend an initial or subsequent mental health visit8-10,11 and less than 
10%8,11 adhere to a full treatment course. This lack of adherence may be due to 
unengaged providers and staff67 and limited resources to ensure depression 
evaluation, treatment, and follow-up.68,27  Ob/Gyn clinics need a stepped care 
program such as RAPPID to ensure that  they adequately address perinatal 
depression and improve patient related outcomes.21  
 Translating integrated, stepped-care models to obstetric settings could 
provide a solution to this critical public health issue.  The successful clinical 
resolution of depression symptoms is uncommon in obstetric settings because 
major gaps in depression care exist.32  It is well-established that integrated care, 
such as stepped and collaborative care models and medical homes, effectively 
integrate depression treatment into primary care settings and improve the  quality 
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of mental health care and depression outcomes.69 Such approaches have been 
introduced and evaluated in Ob/Gyn settings70-73 but the data in this area 
remains limited. For example, one study found that a collaborative care 
approach, which consisted of team management, tracking systems, weekly 
structured case reviews with a psychiatrist, depression care manager, and co-
located clinician, was effective in reducing depression symptoms by at least 50% 
at 12 months.  However,  only 7% of the study population was pregnant.70   Two 
other studies that included only postpartum women and women who were not 
pregnant,71,74 emphasize both the promises and limitations of these prior 
studies.74  This shows that there is a need for effective approaches for 
addressing depression Ob/Gyn settings.  Others are currently testing 
collaborative care approaches in Ob/Gyn settings but have not yet shown 
improved depression or treatment outcomes.72,73  Since these models have not 
been fully adapted to, nor evaluated in obstetric settings, there is a considerable 
unmet need and opportunity to improve and optimize care for pregnant women 
with depression. As detailed in our conceptual model in Figure II, RAPPID is 
based on the guiding principles of collaborative care.   
  Health care reform presents unprecedented opportunities to design and 
test new integrated care models, such as stepped care, to improve patients' 
access to services, improve care quality, and lower overall health-care costs.  
Stepped care models involve initial determination of treatment based on illness 
severity and intensification of care (such as stepwise increases in dose of 
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antidepressant medication) for those with persistent illness.  Despite treatment 
success, these collaborative care models depend on care management facets 
that are not reliably reimbursed and, therefore, their broad implementation, 
dissemination, and associated treatment improvement are not realized.75  The 
term “voltage drop” has been used to describe the less robust results found when 
collaborative care approaches are implemented in low resource real-world 
settings.76  Our new stepped care approach, RAPPID, will be cost-effective 
because it leverages Ob/Gyn providers and staff already working in the Ob/Gyn 
setting.  It will be sustainable because it is modeled on our successful, 
sustainable, and widely used model that provides psychiatric care for pediatric 
populations.   
 The Massachusetts Child Psychiatry Access Project (MCPAP)77,78 
provides a successful, sustainable, and widely used model for providing 
psychiatric care in primary care settings that can be translated to Ob/Gyn 
settings.  MCPAP was created and piloted at UMass Medical School in 2005 
because children were unable to access psychiatric care.  There were not 
enough child psychiatrists, and pediatricians were not equipped to manage 
children’s psychiatric needs. While pediatric providers have an essential role in 
detecting and treating psychiatric concerns in children, children’s needs for 
mental health care were not being met because pediatricians lacked training and 
access to necessary resources to help assess and treat these children. The 
MCPAP program has addressed this problem by delivering telephone psychiatric 
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consultation and resource provision/referrals to support pediatric providers in MA.  
Regional teams provide assessment and treatment support, face-to-face 
consultations, resource provision/referral, and ongoing education for pediatric 
providers.77-79 MCPAP ensures that the 1.5 million children/adolescents in the 
state of MA have access to psychiatric care via their pediatrician; currently, 97% 
of pediatric providers are enrolled (425 practices enrolled; 1,230 of 1,268 MA 
pediatricians, 323 of 331 of MA pediatric nurse practitioners). The cost of the 
program, including administrative expenses, is $2 per child/adolescent per  year 
($0.16 per month) or $3 million for the 1.5 million children in Massachusetts.78 
Enrolled pediatric providers report a dramatic improvement in their ability to meet 
the psychiatric needs of their patients.77,78 MCPAP is cost-effective because it 
requires only 6 full time psychiatrists, therapists, and coordinators to serve the 
entire state.  MCPAP has also been utilized in 32 states in the U.S. which led to 
the establishment of the National Network of Child Psychiatry Access Programs 
(http://nncpap.org/) which promotes the development, sustainability, and quality 
of child mental health and psychiatry access programs across the country.77-79 
Because it is modeled on MCPAP, our RAPPID Program is similarly feasible and 
sustainable and carries the same potential for widespread dissemination and 
implementation. 
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CHAPTER I   
INTRODUCTION 
 
 Based on the MA Child Psychiatry Access Project (MCPAP) model, we have 
created a similar population-based program to help Ob/Gyn providers address perinatal 
depression – MCPAP for Moms.  In 2013, MA passed legislation that increased funding 
to expand the existing MCPAP, creating MCPAP for Moms to address perinatal 
depression.79  Using the additional resources provided by this funding, our team 
developed MCPAP for Moms.79  MCPAP for Moms aims to ensure that Ob/Gyn 
providers can detect, assess, treat, and/or refer women with perinatal depression 
throughout Massachusetts.  Similar to MCPAP, our new program MCPAP for Moms 
provides Ob/Gyn clinics/practices throughout MA with immediate telephonic psychiatric 
consultation and resources and referrals to women and their providers.  This statewide 
program is staffed with 1 full time equivalent perinatal psychiatrist and 2.3 full time 
equivalent coordinators. Regional teams provide assessment and treatment support, as 
needed one time face-to-face consultation, and resource provision/referrals to help 
providers address perinatal depression.78,79  The overall resource demands are low. 
The cost of the program, including administrative expenses, is $4.16 per perinatal 
women per year ($0.35 per month) or $600,000 for the 144,000 perinatal women MA 
has annually. Thus, MCPAP for Moms is within grasp of most Ob/Gyn clinics/practices 
and health systems because it provides a population-based approach to addressing 
perinatal depression at a low cost. 
  MCPAP for Moms now needs to be strengthened to proactively work with Ob/Gyn 
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clinics to help them develop a systematic stepped care approach to ensure that their 
patients do not fall through cracks in the depression care pathway.  To achieve full 
remission of depression symptoms, women with perinatal depression must:  1) be 
recognized via screening; 2) be assessed; 3) initiate treatment; 4) receive adequate 
treatment; and 5) respond to treatment.80  Our pilot work demonstrates that there are 
still gaps in this depression care pathway because MCPAP for Moms does not include 
the more intensive implementation and follow-up components that Ob/Gyn practices 
and their patients need.21  Our work indicates that Ob/Gyn practices need additional 
support and resources to proactively help them implement and sustain depression 
screening and ensure adequate assessment and treatment of the women they serve.  
Thus, while our implementation assessment indicates that MCPAP for Moms provides 
access to invaluable resources that constitutes an enhanced form of usual care, 
emerging data suggest that additional intervention implementation and components are 
needed to ensure that women do not fall through cracks in the depression care 
pathway.   
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Figure I Progression to RAPPID
 
 In response, we have built on MCPAP for Moms and developed the Rapid 
Access to Perinatal Psychiatric Care in Depression Program (RAPPID), a 
comprehensive and proactive program that could result in improved perinatal 
depression outcomes and treatment rates perinatal women. In addition to the 
psychiatric consultation and resource provision/referrals provided by MCPAP for Moms, 
RAPPID also provides: (1) clinic-specific implementation of stepped care, including 
training support and toolkits; and (2) proactive patient monitoring, treatment 
engagement, and stepped treatment response to depression screening/assessment.  
Drawing on implementation frameworks,81-84 RAPPID will provide clinic-specific 
implementation assistance and step-by-step guidance to help practices systematically 
recognize, assess, and treat depression in an efficient and sustainable manner.   
The stepped care treatment response will provide specific treatment protocols in 
response to illness severity. This approach will allocate the most intensive resources to 
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those women with corresponding need. All practice patients who screen positive for 
depression will be entered into a depression registry to receive close monitoring and 
engagement strategies to increase treatment initiation, adherence, adequacy, and 
response.  To balance effectiveness, sustainability, and dissemination ability, we have 
designed RAPPID to leverage and build on MCPAP for Moms along with resources that 
already exist in Ob/Gyn settings.   
RAPPID Conceptual Model: RAPPID aims to improve the delivery of perinatal 
mental health care at multiple levels.85,86 The conceptual basis for RAPPID rests on the 
Chronic Care Model.  Wagner created the Chronic Care Model in response to 
reviews87,88 suggesting that health outcomes were most improved by multi-component  
practice changes that increase provider expertise and skills, educate and support 
patients, make health care delivery more team-based and planned, and maximize the 
use of health information systems. Collaborative care models can improve mental and 
physical outcomes for individuals with mental illness across a wide variety of care 
settings, and they provide a robust clinical and policy framework for integrating obstetric 
and depression care.69  Collaborative care models generally focus on chronic illnesses, 
whereas the majority of perinatal depression is new onset.33  Thus, we have designed 
RAPPID to not only detect and treat chronic depression but also to detect/intervene 
early before chronic depression sets in.  
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 Our systematic review of perinatal depression treatment in Ob/Gyn settings 
suggests that RAPPID will seal gaps in care by improving the detection, assessment, 
referral, and/or treatment of depression in these settings.  Systematic reviews 
performed prior to ours have not found that screening improves depression outcomes in 
Ob/Gyn settings. Our systematic review examined a wider range of study designs and 
outcomes to determine whether depression screening in outpatient obstetric settings 
increases mental health care use.  Seventeen articles representing a range of study 
designs, including 1 RCT and 1 cluster RCT, met our pre-defined criteria and were 
included. We found that screening alone led to an average 22% participation in ≥1 
mental assessment among women who screened positive for depression.  The rate of 
attendance of at least 1 mental health assessment doubled when screening was done 
in conjunction with any of the following:  patient engagement strategies (44%), on-site 
assessment (49%), and provider training (54%).  Higher rates of mental health care use 
(79%) occurred when interventions were combined and included resource combinations 
provided to women, provider training, on-site assessment, implementation assistance, 
and access to mental health consultation for perinatal care providers.  While screening 
alone led to only 22% mental health care use during the perinatal period, this rate 
improved 2-4 fold when intervention programs are in place to ensure that women 
receive adequate treatment. Our review suggests that screening in conjunction with 
multi-modal stepped care strategies improves detection, assessment, referral, and/or 
treatment of depression in perinatal care settings.  We designed RAPPID to include the 
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multi-modal stepped care strategies that our review found increases the frequency of 
mental health care use.  
Formative Work 
 Our proposed intervention, RAPPID, is designed to overcome several previously 
identified barriers and leverage facilitators identified in our formative studies. Before 
developing RAPPID, we conducted 3 formative research studies with obstetric providers 
and staff, and postpartum and pregnant women, to better understand how to address 
depression in obstetric settings.34,36,37 After screening women for depression (n=110), 
we identified those with significant depression symptoms (n=46) and conducted semi-
structured interviews to better understand how their interactions with health care 
providers contribute to untreated perinatal depression.89 Barriers perceived by these 
women included providers declining to treat them with medication during pregnancy, 
and providers’ not understanding women’s needs and/or available treatment options.  
We also conducted two qualitative studies, one with postpartum women and the other 
with obstetric providers, to further investigate barriers and facilitators to perinatal 
depression care in obstetric settings.  Both patients and providers suggested 
empowering women to seek help through psycho-education, provision of resources, 
validation of women’s experiences, and awareness regarding language and interactions 
that could be interpreted as stigmatizing.34,36,37 Both also recommended that depression 
care become a routine part of perinatal care via pertinent training for providers/staff and 
improved collaborations with mental health providers.  These formative studies led us to 
hypothesize that transforming obstetrical practice to include depression treatment would 
improve women’s access to, and engagement in, treatment and, thereby, improve 
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depression related outcomes.  
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CHAPTER II 
RAPPID DEVELOPMENT AND BETA TESTING 
 
  The purpose of our formative research study was to design and beta test the 
implementation of RAPPID.   
Development of RAPPID 
 Study Setting.  Research was conducted in the Ob/Gyn Department of a large 
tertiary care referral center in an academic medical center in central Massachusetts.  
The study clinic site has 12 Ob/Gyn attending physicians, 2 nurse practitioners, 20 
Ob/Gyn residents that rotate through the clinic, 4 nurses, 1 patient care assistant, and 3 
clinical administrative support staff.  In fiscal year 2013-2014, the clinic site served 691 
obstetric patients; among the prenatal care population, approximately 20.4% are Latina, 
13.8% are Black, 53.7% are non-Latina white, 5.7% Asian, and 6.4% are from other 
race/ethnicities.  The clinic population was insured by Medicaid (69%), commercially 
insured (23%), Medicare (4%), and self-pay/free care (4%).   
 Work group participants.  A multidisciplinary work group consisted of a 
purposeful sample of perinatal (n=6) and psychiatric health care professionals (n=1) 
(Table I).  Work group participants were recruited via email and direct personal 
communications at faculty, resident, and staff meetings.  Departmental support in the 
form of release from other clinical or administrative responsibilities was provided for the 
work group participants.  
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The multidisciplinary work group provided iterative feedback on the core program 
components and uncovered barriers and facilitators to the implementation of RAPPID.  
Nine work group meetings were held over a period of 6 months; each were devoted to 
reviewing and providing feedback on specific components of the program and the 
associated products and procedures (Table II).  The work group initially identified goals 
and strategies for addressing perinatal depression in obstetric settings in general and 
also in their specific clinic.   The work group provided iterative feedback as RAPPID 
components were developed and refined.   For example, after the initial treatment 
protocols proposed were deemed unrealistic and impractical for Ob/Gyn settings by the 
working group, they were adapted to minimize the time burden for Ob/Gyn providers 
and staff, while also meeting clinical standards.   
 Advisory board.  A multi-stakeholder advisory board formed and met regularly 
with the Principal Investigator (PI) (NB) to provide input on acceptability, feasibility, and 
perceived barriers and facilitators to implementing RAPPID.  The board included a 
woman with a history of postpartum depression (PPD), 3 members from the 
Massachusetts Legislative Commission on PPD including an Ob/Gyn attending 
physician, and 3 experts in providing access to psychiatric consultation and care 
coordination psychiatric telephone consultation to primary care providers. Program 
components and products were adapted based on iterative feedback from both the work 
group and advisory board, resulting in a beta version of the RAPPID components ready 
for beta testing.    
Components of RAPPID program 
 RAPPID (available from first author upon request) consists of:  (1) access to the 
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immediate resource provision/referrals and psychiatric telephone consultation for 
Ob/Gyn providers; (2) Ob/Gyn clinic-specific implementation of depression screening, 
assessment and treatment, including training and implementation support and toolkits; 
and,  (3) approaches to facilitating treatment engagement and response to depression 
screening/assessment.   
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Approaches to 
facilitating 
treatment 
engagement 
and stepped 
treatment 
response to 
depression 
screening/ 
assessment   
 Stepped care involves initial determination of treatment based on 
illness severity followed by intensification of care as necessary (such as 
stepwise increases in dose of antidepressant medication) for those with 
persistent illness.  The following strategies will be used to implement 
screening:  training, toolkits, systematic screening, patient engagement, 
and stepped care protocols. 
Training.  A total of 3, 2-hour trainings for practice providers and 
staff. Train and assist the RAPPID clinics to provide care for depression, 
including systematic screening and monitoring for depression. Providers 
will be trained how to use to screen and assess depression, to include 
depression in treatment plans, and to discuss the risks and benefits of 
antidepressant use during pregnancy and lactation.  Providers also 
receive training in how to de-stigmatize depression and activate women 
to seek help.  
 Toolkits. Practices are provided with screening, referral and 
treatment protocols.  Protocols include specific instructions for specific 
ranges of scores on the Edinburgh Postnatal Depression Scale (EPDS) 
to prompt assessment and treatment steps.  Psychoeducational 
resources to give to women are also provided. 
 Systematic screening. Work with each practice to develop an 
individualized approach to depression screening. This will include 
establishing office procedures for screening.  Determine the timing, 
location, and setting for screening and discussion of 
screening/treatment/referral.  Work with clinic providers/staff to tailor 
screening procedures to be acceptable and helpful. 
 Patient engagement.  The Ob/Gyn providers and staff are trained 
to provide psychoeducation. The medical assistant/champion will deliver 
psychoeducation when women screen positive for depression as part of 
the stepped care treatment response and when he/she calls patients to 
follow-up regarding treatment participation as part of the proactive patient 
monitoring.   During follow-up calls the medical assistant/champion will 
offer referral to therapy if the patient is not engaged in psychotherapy or 
behavioral health treatment.   
 Psychoeducation for depression emphasizes instruction and 
education on a variety of topics relating to depression, including 
symptoms, the expected clinical course and prognosis, treatment options 
and strategies, and signs of relapse.92,93   
  We will match the severity and complexity of patients' disorders to 
the appropriate level of care. Psychopharmacology, when indicated, will 
be provided by the Ob/Gyn providers and licensed independent 
practitioners guided by MCPAP for Moms perinatal psychiatry 
consultation as needed.  Psychoeducation and resource provision will be 
offered during perinatal visits according to the stepped care protocol.  
Patients with severe, complex, or treatment refractory illness will be 
referred to a psychiatric provider according to stepped care protocol and 
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clinical judgment of the Ob/Gyn.  Referral to psychiatrists or psychiatric 
nurse will be facilitated by the RAPPID medical assistant/champion.  
During subsequent follow-ups visits, patients will be stepped up to a 
higher level of care if there is evidence of clinical deterioration or lack of 
improvement.   
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Beta testing of RAPPID 
This study was reviewed by the University of Massachusetts Medical School 
Institutional Review Board (IRB) and received an exemption because no identifying or 
demographic data for patient participants was collected.  Patients were screened for 
depression with the Edinburgh Postnatal Depression Scale (EPDS)94.  Provider and 
staff participants (Table I) were recruited for the beta testing and focus group evaluation 
of RAPPID via email and direct personal communications at faculty, resident, and staff 
meetings.  Baseline attitudes toward screening were assessed prior to the study by 
asking Ob/Gyn providers and staff participants, “Do you routinely screen for perinatal 
depression using a validated screening tool?” All the Ob/Gyn attending and resident 
physicians, nursing staff and front desk staff working at the clinic were invited to attend 
a 1.5 hour training conducted by the PI (NB) and an attending Ob/Gyn from an outside 
institution.  A beta test was then conducted at the study clinic site on Mondays from 
November - December, 2013. During the period of the beta test, 50 patients were 
served by the Ob/Gyn providers and staff participating in the beta test.   
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  The Ob/Gyn providers and staff participating in the beta test invited women to 
participate by being screened for depression.  Patient participants were individuals who: 
(1) were receiving obstetric care at the study clinic site during one of five consecutive 
Monday clinics during the study period; (2) were receiving care from one of the 4 
Ob/Gyn providers participating in the beta test; (3) consented to be screened for 
depression; (4) were pregnant or postpartum; (5) over 15 years of age; and, (6) English-
speaking.  
The EPDS is a validated and widely used screening questionnaire that assesses 
depression during pregnancy and in the postpartum period 94.  The EPDS is self-
administered and consists of 10 multiple-choice items that rate the intensity of 
symptoms of depression for the preceding 7 days.  The total score ranges from 0-30 
with higher scores indicating greater severity of symptoms.94  The cut-off scores used to 
indicate possible depression range from 9-13.  When using a cut-off of ≥9 for ‘‘possible’’ 
depression , and ≥12 for ‘‘probable’’ depression, the EPDS has a sensitivity of 86% and 
specificity of 78%.94  Consistent with prior studies,95-101 we used a cut-off of 10 to 
ensure that we captured most or all women with EPDS scores indicating that further 
assessment for depression is needed.  The screening component of the beta testing of 
RAPPID included having Ob/Gyn provider and staff screen pregnant and postpartum 
clinic patients with the EPDS.  Once the EPDS was completed, providers followed the 
RAPPID screening protocol and utilized the program components (Table II).  The PI 
(NB) served as the psychiatric consultant.  
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 Assessment of beta testing.  After the beta test, we assessed provider and staff 
participation in RAPPID and their perceptions of RAPPID components.  An attendance 
log was used to assess training attendance and medical record review to obtain rates of 
administration and documentation of screening with the EPDS.  Utilization of 
telephone/email consultation and the provider toolkit was assessed via a call/email log 
and single focus group. The medical records were reviewed by the Research Assistant 
(RA) to determine rates of screening and documentation of screening results.   
 After the beta testing, a 90 minute tape-recorded focus group was conducted to 
identify barriers and facilitators to program implementation of RAPPID.  The focus group 
consisted of a purposeful sample of Ob/Gyn providers and staff who had participated in 
the beta testing (Table I).  Participants responded to open-ended study probes on 
barriers and facilitators to addressing perinatal depression during the focus group 
discussions.   
 The research team debriefed after the focus group to identify general themes and 
immediate impressions of the focus group.  Interview data were coded by the PI (NB) 
and RA (SH) for concepts and themes.  Within this framework, increasingly narrow and 
specific categories of concepts and themes were defined to condense raw data and to 
identify common themes.  The reliability of findings were enhanced by the coding of 
data by more than one researcher and comparison of findings with our 36,102 and others 
previous research.50 103 49 104  RAPPID components were then revised based on focus 
group feedback and after input from the advisory board. 
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Screening results from beta testing 
 The beta testing participants consisted of a multidisciplinary group of 22 Ob/Gyn 
providers and staff (Table II).  Prior to beta testing, 100% of the provider and staff 
participants answered “no” to the question, “Do you routinely screen for perinatal 
depression using a validated screening tool?”   
 Ninety-three percent (13 out of 14) of the providers and staff who practice in the 
clinic attended the training.  Forty out of the 50 women (76%) invited to be screened 
with the EPDS completed the screen.  Ten eligible patients were not screened because: 
(1) they chose not to be screened; or, (2) consented to screening yet did not understand 
or complete the EPDS form. The EPDS was documented in the chart in 95% of patients 
who were screened (n=38).  Thirty-five percent (n=14) of patients had an EPDS score of 
≥10.   No women scored positive on the self-harm question in the EPDS (question 10).  
Every participating Ob/Gyn provider screened ≥ 50% of their patients, in contrast to 
baseline reports by participating Ob/Gyn providers that they were not screening 
systematically with a validated screening tool at all prior to implementation.   
During the 5-week study period, the consulting psychiatrist provided four 
consultations to the obstetric providers, three via email and 1 via the telephone.  Three 
of the four consultations focused on the assessment of depression and use of 
antidepressants during pregnancy and/or lactation.  One consultation asked for 
assistance with diagnostic clarification and treatment planning.   
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Findings from focus group on beta-testing of RAPPID 
RAPPID components need to be enhanced to help patients complete the 
EPDS screen and engage in mental health care.   
Several participants noted that a subset of patients did not complete the EPDS or 
did not see the value of mental health care and were hesitant to engage in treatment. 
The clinic social worker found this to be a major barrier to addressing their depression. 
For example, 
 “I would get messages and then I would call them and see them at their 
next visit and they didn’t want help.”  
Several participants recommended providing patients with a written and verbal 
explanation of the EPDS to underscore its importance in obstetric care.  They also 
suggested providing resources to engage patients who screen positive and decline a 
referral to mental health treatment.   A card that includes a link to a website with 
resources was suggested in order to facilitate them reaching out for mental health care 
when ready.  They also suggested providing psycho-educational materials to patients 
during nursing intake appointments and also placing these materials throughout the 
clinic.   
Recognizing how common depression is and screening with a validated 
screening tool reinforces the need to screen with the EPDS. 
Provider participants noted that they felt more engaged after having participated 
in the training and beta testing.  Several participants were struck by the fact that 
depression is twice as common as gestational diabetes.  They also reported that the 
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screening process itself increased patient and provider awareness of perinatal 
depression.  They noted that the EPDS uncovered symptoms that they would not have 
detected without it, thereby reinforcing the importance of systematically screening for 
depression with a validated screening tool.  One resident noted: 
“It’s shocking to me how many people would say [they experience 
depressed mood] sometimes or every day…  I’m shocked that the patient 
is actually answering that they have those feelings on a regular basis, I 
would never think that just talking to them.”  
Tailoring RAPPID to the clinic setting facilitates providers and staff 
screening, assessing, referring for treatment, or treating depression.   
Participants noted that tailoring RAPPID to the study clinic’s unique setting 
ensured providers and support staff needs were met during implementation. They noted 
that screening “no longer felt like they were trying to fit a square peg into a round hole” 
as it had when they had tried to implement screening in the past. One nurse explained: 
 “I think it has been totally excellent that you had our input about how the 
clinic ran before you [implemented screening]”… You used us for 
feedback and input and that was very important.”  
Several participants reflected that engaging providers and staff in the depression 
screening process leads to better obstetric care for women.  Several noted that it was 
“easy” to document the screen and they did not experience it as an “undue burden” 
because the process was well thought out and designed to be efficient.    
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Having foundational knowledge and skills and access to consultation with 
a perinatal psychiatrist provides needed reassurance and expertise and facilitates 
Ob/Gyn providers and staff screening and managing depression. 
The participants noted the training was essential because it equipped them to 
provide depression care.  They particularly appreciated the concrete instructions about 
how to initiate and titrate antidepressants.   Knowing they had access to consultation 
with a perinatal psychiatrist provided needed reassurance and empowered them to 
make clinical decisions about their patients’ mental health status.  One resident noted 
that she felt much less isolated knowing that she could call the perinatal psychiatrist and 
thus the screening, assessment, and treatment process felt “easy.”  Another resident 
noted: 
“…we felt comfortable and we emailed [or called] the RAPPID psychiatrist 
and said what we want to do, [and] do you think it’s reasonable… We also 
feel like we’re supported, so it’s easier to start [treatment] when you have 
someone who is in the specialty that can back you up.”  
Discussion of RAPPID development and beta testing 
 Iterative feedback and problem solving with the work group and advisory group 
resulted in the development of a new program, RAPPID.  Beta testing and evaluation of 
RAPPID was favorable and indicates that it is feasible to use training and 
implementation assistance to help Ob/Gyn providers and staff implement a multi-
component program that incorporates depression screening and treatment into obstetric 
care.    
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 Our findings from the beta-test build on prior research suggesting that both 
providers and patients need to be empowered to participate in screening, assessment, 
and treatment of depression in obstetric settings 32,36,40,105,106 and , by extension, 
prevent women in need from falling through the cracks in the depression care pathway.  
Our beta-test also suggests that RAPPID builds provider capacity to address 
depression and supports Ob/Gyn providers and staff in taking on screening, assessing, 
and referring for treatment or treating depression.  The most potent facilitators to 
addressing depression appear to be: (1) clinic specific tailoring of the RAPPID 
components; (2) knowledge and skills obtained during training; and, (3) access to real-
time consultation with a perinatal psychiatrist.  The process of screening also appears to 
increase awareness about the importance of screening with a validated tool.   
Our findings are  consistent with prior studies suggesting that the capacity of 
perinatal health care professionals to detect and address depression may be enhanced 
by providing them with education, resources, and access to mental health consultation 
32,36,40,105,106.  The need to further improve RAPPID to better engage women makes 
sense given prior studies indicating that empathic depression screening and discussion 
of mental health concerns is critical to engaging women in mental health care 32,35,37,49. 
Our findings are also consistent with prior studies showing that multi-modal strategies 
for detecting, assessing, referring and/or treating depression in obstetric settings result 
in an increase in mental health care use when compared to screening alone 
11,60,74,95,96,106,107,97,105,108.  .  
Our beta-test has several strengths and weaknesses.  One of the strengths is 
that we were able to develop a new program, RAPPID, using an iterative process in 
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which we elicited provider feedback and tailored the intervention to work in the “real-
world.”  Our process of eliciting ideas and feedback from perinatal care professionals as 
to how the program should be implemented ensured screening was efficient and 
minimized burden to the providers and staff involved.  This led us to refine the 
implementation process and develop and step-by-step approach to helping Ob/Gyn's 
integrate depression care into their clinic workflow. In order to be sustainable, RAPPID 
is designed to utilize existing clinical resources rather than study research-funded 
resources to screen and address depression, carrying the potential for real-world 
implementation.  We also obtained information that allowed us to enhance RAPPID by 
integrating proactive patient engagement and monitoring into the existing clinic 
procedures/operations.  This includes training Ob/Gyn clinics to provide Motivational 
Interviewing to engage patients, proactive tracking of all women in the clinics who 
screen positive on the EPDS, and a stepped care treatment response to depression 
screening/assessment. 
 Our beta-test is limited in that we only worked with one clinic in one academic 
medical setting, with a subset of motivated providers and staff.  However, our study 
allowed us to develop a critical process for tailoring RAPPID implementation that can be 
translated to other clinics sites.  It is likely that other challenges will occur with different 
patient populations, providers, and staff clinical settings.  We also do not have any 
follow-up data on the women including adherence to depression care and improvement 
in depression symptoms; in as much, we are unable to link the screening and referral 
process to various patient related outcomes.   Future studies are needed to evaluate 
  
 
xl 
RAPPID in multiple diverse clinical settings, evaluate patient outcome data, and enrich 
our understanding of patient perceptions of screening.     
  Our approach engaged the study clinic site in the process and design of 
RAPPID.  Although further evaluation is indicated, our beta-test indicates   RAPPID 
shows promise in that it may be able to overcome barriers to addressing perinatal 
depression in obstetric settings.   
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CHAPTER III 
RAPPID PILOT STUDY 
 
With the intention of conducting a large-scale multi-site cluster RCT comparing 
RAPPID with enhanced usual care, we are currently conducting a pilot cluster RCT (4 
sites) to reveal and address feasibility issues.  Modeled after Kraemer et al.’s 
recommendations for performing pilot mental health services studies109 to guide the 
design and implementation of larger effectiveness studies, we are evaluating the 
“feasibility of recruitment, randomization, retention, assessment, procedures, and 
implementation”109 of RAPPID. In our pilot study, enhanced usual care consists of 
screening/referral and access to our statewide population based program, MCPAP for 
Moms as it is now standard of care in MA.  The designation of ‘enhanced’ 
acknowledges that most Ob/Gyns in other states do not have access to this level of 
psychiatric consultation and resource provision/referrals (Table I).110  In our pilot cluster 
RCT, we are comparing 2 clinics in which providers/staff (n=18) and perinatal women 
(n=30) participate in RAPPID, to another 2 clinics in which providers/staff (n=18) and 
women (n=30) participate in enhanced usual care.   
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staff); the provider/staff numbers exceeded our calculated needs.  We have retained all 
four clinic study sites and ≥ 98% of our provider and staff participants.  Our RAPPID 
intervention sites are screening ≥ 95% of their patients as compared to pre-RAPPID 
implementation when there was no systematic screening with validated screening tools. 
We are also exceeding our patient recruitment goals.  Among patient participants from 
RAPPID clinics screening positive for depression (n=16), 81% (n=13) have been offered 
and initiated depression treatment; this finding compares with the rate of 62% (n=8) 
observed in the enhanced usual care group (n=13). This suggests that RAPPID has the 
potential to differentially improve treatment rates as compared with enhanced usual 
care (access to MCPAP for Moms).  
  Our ongoing pilot cluster RCT has also uncovered barriers and facilitators to 
implementing RAPPID and conducting a cluster RCT to test its effectiveness.  We have 
found that clinic characteristics contribute significantly to practice readiness for 
screening and addressing depression. Challenges include a lack of leadership, high 
provider and staff turnover rates, high patient volume, and use of multiple electronic 
medical records. Conversely, RAPPID implementation is facilitated by strong 
leadership, lower turnover rates, and lower clinic volume.  We are using this critical 
feasibility data to refine the cluster RCT design for this U01.   Our pilot study also 
identified that providers need more robust stepped care approaches to ensure that they 
screen for and rule-out patients with  bipolar disorders prior to referring for or initiating 
treatment.   
 We are also currently conducting an additional sub-study to better understand 
how to screen for bipolar disorder in Ob/Gyn settings.  We are recruiting and assessing 
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perinatal women who screen positive for depression (EPDS ≥10) and meet criteria for 
bipolar disorder based on the Mini International Neurodiagnostic Interview.  Thus far, 
four of six patient participants (67%) have undiagnosed bipolar disorder and three of 
these four (75%) were being treated with an antidepressant (2 by Ob/Gyn and 1 by 
PCP).  This finding is concerning because treatment with an antidepressant can 
exacerbate bipolar disorder and increase risk of manic symptoms.  To address this 
critical issue, we have incorporated a well-validated bipolar disorder screen into our 
stepped care treatment response.  The lessons learned from our pilot study will allow 
us to refine RAPPID to further help Ob/Gyn providers detect, treat, and/or refer women 
with depression and/or other mental illnesses for ongoing treatment in pregnancy and 
the postpartum period. 
Future directions 
 As described earlier, our pilot cluster RCT was designed with the a priori 
intention of performing a larger cluster RCT to test the effectiveness of RAPPID as 
compared with enhanced usual care.  This critical feasibility data will be used to refine 
the design for a cluster-RCT to test the effectiveness of RAPPID.  The lessons learned 
from our pilot study will also be used to refine RAPPID to further help Ob/Gyn providers 
detect, treat, and/or refer women with depression.  The overall goal of the cluster RCT 
will be to compare two active interventions, enhanced usual care (access to MCPAP for 
Moms) vs. RAPPID in a cluster RCT.  First, we will further refine RAPPID based on our 
pilot data.  Second, we will test RAPPID in a cluster RCT of Ob/Gyn clinics randomized 
to either RAPPID or enhanced usual care.  More specifically, we will compare 
depression severity and treatment participation among depressed women that receive 
  
 
xlv 
care from enrolled clinics throughout the perinatal period.  We will also examine 
provider/staff fidelity to RAPPID (secondary outcome) and estimate costs of RAPPID 
and enhanced usual care indicators of potential savings.  Third, we will disseminate the 
trial findings and recommendations. 
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CHAPTER IV 
FINAL SUMMARY AND CONCLUSIONS 
  Similar to the MCPAP, RAPPID has the potential to spread to other states.  
Each of the 32 states that have a program modeled on MCPAP has unique funding 
mechanisms including grants from state legislatures, private foundations, or Medicaid 
funding. In fiscal year 2014, Connecticut, the District of Columbia, New Jersey, Oregon, 
and Wisconsin passed budgets with funding for new child psychiatry access 
programs.79  With movement of health care funding to an accountable care model, 
some accountable care organizations (ACOs) may also fund their own MCPAP 
programs.  In order to share the program costs with commercial insurers, the 
Massachusetts legislatures recently added budgetary language stating that as of 2015, 
commercial insurers will have to pay a surcharge for the program thus enhancing 
sustainability.79  This unprecedented legislative decision provides direct evidence of the 
power of the MCPAP model to change the regional and national landscape for pediatric 
mental health care.  As evidenced by the support already provided through Legislators 
and the MA Department of Mental Health, we can replicate this in perinatal mental 
health. MCPAP was also recently recognized by the Agency for Healthcare 
Research and Quality (AHRQ) in their Health Care Innovations Exchange initiative to 
promote diffusion and uptake of innovations.79,111 AHRQ noted that MCPAP, “has been 
broadly accepted by primary care clinicians and enhances their ability to treat children 
and adolescents with mental health issues.”111  This illustrates our potential power to 
transform Ob/Gyn practice, even within the context of limited resources.   
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 Implementing, testing, and disseminating RAPPID could propel the perinatal 
mental health field forward.  If shown to be effective, RAPPID has the potential to have 
a tremendous impact on the many mothers, families, and babies affected by 
depression.  
 
  
  
 
xlviii 
BIBLIOGRAPHY 
1. Grote NK, Bridge JA, Gavin AR, Melville JL, Iyengar S, Katon WJ. A meta-
analysis of depression during pregnancy and the risk of preterm birth, low birth weight, 
and intrauterine growth restriction. Arch Gen Psychiatry 2010;67:1012-24. 
2. Britton HL, Gronwaldt V, Britton JR. Maternal postpartum behaviors and mother-
infant relationship during the first year of life. J Pediatr 2001;138:905-9. 
3. Forman DR, O'Hara MW, Stuart S, Gorman LL, Larsen KE, Coy KC. Effective 
treatment for postpartum depression is not sufficient to improve the developing mother-
child relationship. Dev Psychopathol 2007;19:585-602. 
4. Deave T, Heron J, Evans J, Emond A. The impact of maternal depression in 
pregnancy on early child development. BJOG 2008;115:1043-51. 
5. Paulson JF, Keefe HA, Leiferman JA. Early parental depression and child 
language development. J Child Psychol Psychiatry 2009;50:254-62. 
6. Segre LS, O'Hara MW, Arndt S, Stuart S. The prevalence of postpartum 
depression: the relative significance of three social status indices. Soc Psychiatry 
Psychiatr Epidemiol 2007;42:316-21. 
7. Martinez-Schallmoser L, Telleen S, MacMullen NJ. The effect of social support 
and acculturation on postpartum depression in Mexican American women. Journal of 
transcultural nursing : official journal of the Transcultural Nursing Society / Transcultural 
Nursing Society 2003;14:329-38. 
8. Smith MV, Shao L, Howell H, Wang H, Poschman K, Yonkers KA. Success of 
mental health referral among pregnant and postpartum women with psychiatric distress. 
Gen Hosp Psychiatry 2009;31:155-62. 
9. Carter FA, Carter JD, Luty SE, Wilson DA, Frampton CM, Joyce PR. Screening 
and treatment for depression during pregnancy: a cautionary note. Aust N Z J 
Psychiatry 2005;39:255-61. 
10. Marcus SM, Flynn HA, Blow FC, Barry KL. Depressive symptoms among 
pregnant women screened in obstetrics settings. J Womens Health (Larchmt) 
2003;12:373-80. 
11. Rowan P, Greisinger A, Brehm B, Smith F, McReynolds E. Outcomes from 
implementing systematic antepartum depression screening in obstetrics. Archives of 
women's mental health 2012;15:115-20. 
12. Cripe SM, Frederick IO, Qiu C, Williams MA. Risk of preterm delivery and 
hypertensive disorders of pregnancy in relation to maternal co-morbid mood and 
migraine disorders during pregnancy. Paediatr Perinat Epidemiol 2011;25:116-23. 
13. Suri R, Altshuler LA, Mintz J. Depression and the decision to abort. AJ Psychiatry 
2004;161:1502. 
14. Flynn HA, Chermack ST. Prenatal alcohol use: the role of lifetime problems with 
alcohol, drugs, depression, and violence. J Stud Alcohol Drugs 2008;69:500-9. 
15. Gotlib IH, Whiffen VE, Wallace PM, Mount JH. Prospective investigation of 
postpartum depression: factors involved in onset and recovery. J Abnorm Psychol 
1991;100:122-32. 
16. Britton JR. Infant temperament and maternal anxiety and depressed mood in the 
early postpartum period. Women Health 2011;51:55-71. 
  
 
xlix 
17. Pilowsky DJ, Wickramaratne PJ, Rush AJ, et al. Children of currently depressed 
mothers: a STAR*D ancillary study. J Clin Psychiatry 2006;67:126-36. 
18. Weissman MM, Pilowsky DJ, Wickramaratne PJ, et al. Remissions in maternal 
depression and child psychopathology: a STAR*D-child report. JAMA 2006;295:1389-
98. 
19. Beeber LS, Holditch-Davis D, Perreira K, et al. Short-term in-home intervention 
reduces depressive symptoms in Early Head Start Latina mothers of infants and 
toddlers. Res Nurs Health 2010;33:60-76. 
20. Kim JJ, La Porte LM, Corcoran M, Magasi S, Batza J, Silver RK. Barriers to 
mental health treatment among obstetric patients at risk for depression. Am J Obstet 
Gynecol 2010;202:312 e1-5. 
21. Kozhimannil KB, Adams AS, Soumerai SB, Busch AB, Huskamp HA. New 
Jersey's efforts to improve postpartum depression care did not change treatment 
patterns for women on medicaid. Health Aff (Millwood) 2011;30:293-301. 
22. Senate Bill 15  Postpartum Mood Disorders Prevention Act. 2007. (Accessed Oct 
1, 2013, at http://www.ppdil.org/legislation/illinois-senate-bill-15-2007.html.) 
23. An Act Relative to Post Partum Depression, Chapter 313 of the Acts of 2010., 
2010. (Accessed February 15, 2015, at 
http://www.malegislature.gov/Laws/SessionLaws/Acts/2010/Chapter313.) 
24. ACOG Committee Opinion No. 343: psychosocial risk factors: perinatal screening 
and intervention. Obstet Gynecol 2006;108:469-77. 
25. Gynecologists ACoOa. Committee opinion no. 453: Screening for depression 
during and after pregnancy. Obstet Gynecol 2010;115:394-5. 
26. Kuosmanen L, Vuorilehto M, Kumpuniemi S, Melartin T. Post-natal depression 
screening and treatment in maternity and child health clinics. J Psychiatr Ment Health 
Nurs 2010;17:554-7. 
27. Gjerdingen DK, Yawn BP. Postpartum depression screening: importance, 
methods, barriers, and recommendations for practice. J Am Board Fam Med 
2007;20:280-8. 
28. Campagne DM. The obstetrician and depression during pregnancy. Eur J Obstet 
Gynecol Reprod Biol 2004;116:125-30. 
29. Austin MP, Middleton P, Reilly NM, Highet NJ. Detection and management of 
mood disorders in the maternity setting: The Australian Clinical Practice Guidelines. 
Women Birth 2012. 
30. Barnett B. An Integrated Model of Perinatal Care. European Psychiatric Review 
2011;4:71-4. 
31. LaRocco-Cockburn A, Melville J, Bell M, Katon W. Depression screening 
attitudes and practices among obstetrician-gynecologists. Obstet Gynecol 
2003;101:892-8. 
32. Byatt N, Simas TA, Lundquist RS, Johnson JV, Ziedonis DM. Strategies for 
improving perinatal depression treatment in North American outpatient obstetric 
settings. J Psychosom Obstet Gynaecol 2012;33:143-61. 
33. Wisner KL, Sit DK, McShea MC, et al. Onset timing, thoughts of self-harm, and 
diagnoses in postpartum women with screen-positive depression findings. JAMA 
Psychiatry 2013;70:490-8. 
  
 
l 
34. Byatt N, Biebel K, Debordes-Jackson G, et al. Community Mental Health 
Provider Reluctance to Provide Pharmacotherapy May Be a Barrier to Addressing 
Perinatal Depression: A Preliminary Study. The Psychiatric quarterly 2012. 
35. Byatt N, Biebel K, Friedman L, Debordes-Jackson G, Ziedonis D. Women's 
perspectives on postpartum depression screening in pediatric settings: a preliminary 
study. Arch Womens Ment Health 2013;16:429-32. 
36. Byatt N, Biebel K, Lundquist R, Moore Simas T, Debourdes-Jackson G, Ziedonis 
D. Patient, provider and system-level barriers and facilitators to addressing perinatal 
depression Journal of Reproductive and Infant Psychology 2012  30:436-9. 
37. Byatt N, Biebel K, Friedman L, Debordes-Jackson G, Ziedonis D, Pbert L. 
Patient's views on depression care in obstetric settings: how do they compare to the 
views of perinatal health care professionals? Gen Hosp Psychiatry 2013;35:598-604. 
38. Byatt N, Moore Simas T, Lundquist R, Johnson J, Ziedonis D. Strategies for 
Improving Perinatal Depression Treatment in North American Outpatient Obstetric 
Settings. Journal of Psychosomatic Obstetrics & Gynecology 2012 (in press). 
39. Edge D. Falling through the net - black and minority ethnic women and perinatal 
mental healthcare: health professionals' views. Gen Hosp Psychiatry 2010;32:17-25. 
40. Palladino CL, Fedock GL, Forman JH, Davis MM, Henshaw E, Flynn HA. OB 
CARES--The Obstetric Clinics and Resources Study: providers' perceptions of 
addressing perinatal depression--a qualitative study. Gen Hosp Psychiatry 2011;33:267-
78. 
41. Price SK, Corder-Mabe J, Austin K. Perinatal depression screening and 
intervention: enhancing health provider involvement. J Womens Health (Larchmt) 
2012;21:447-55. 
42. Kim JJ, La Porte LM, Adams MG, Gordon TE, Kuendig JM, Silver RK. Obstetric 
care provider engagement in a perinatal depression screening program. Arch Womens 
Ment Health 2009;12:167-72. 
43. Mancini F, Carlson C, Albers L. Use of the Postpartum Depression Screening 
Scale in a collaborative obstetric practice. J Midwifery Womens Health 2007;52:429-34. 
44. McIntosh J. Postpartum depression: women's help-seeking behaviour and 
perceptions of cause. J Adv Nurs 1993;18:178-84. 
45. Edge D. 'We don't see Black women here': an exploration of the absence of 
Black Caribbean women from clinical and epidemiological data on perinatal depression 
in the UK. Midwifery 2008;24:379-89. 
46. Jesse DE, Dolbier CL, Blanchard A. Barriers to seeking help and treatment 
suggestions for prenatal depressive symptoms: focus groups with rural low-income 
women. Issues Ment Health Nurs 2008;29:3-19. 
47. Flynn HA, Henshaw E, O'Mahen H, Forman J. Patient perspectives on improving 
the depression referral processes in obstetrics settings: a qualitative study. Gen Hosp 
Psychiatry 2010;32:9-16. 
48. Kopelman RC, Moel J, Mertens C, Stuart S, Arndt S, O'Hara MW. Barriers to 
care for antenatal depression. Psychiatr Serv 2008;59:429-32. 
49. Dennis CL, Chung-Lee L. Postpartum depression help-seeking barriers and 
maternal treatment preferences: a qualitative systematic review. Birth 2006;33:323-31. 
  
 
li 
50. Sword W, Busser D, Ganann R, McMillan T, Swinton M. Women's care-seeking 
experiences after referral for postpartum depression. Qual Health Res 2008;18:1161-
73. 
51. Abrams LS, Dornig K, Curran L. Barriers to service use for postpartum 
depression symptoms among low-income ethnic minority mothers in the United States. 
Qual Health Res 2009;19:535-51. 
52. Edge D, Baker D, Rogers A. Perinatal depression among black Caribbean 
women. Health Soc Care Community 2004;12:430-8. 
53. Amankwaa LC. Postpartum depression among African-American women. Issues 
Ment Health Nurs 2003;24:297-316. 
54. Nahas VL, Hillege S, Amasheh N. Postpartum depression. The lived experiences 
of Middle Eastern migrant women in Australia. J Nurse Midwifery 1999;44:65-74. 
55. Edge D, MacKian SC. Ethnicity and mental health encounters in primary care: 
help-seeking and help-giving for perinatal depression among Black Caribbean women in 
the UK. Ethn Health 2010;15:93-111. 
56. Shakespeare J, Blake F, Garcia J. A qualitative study of the acceptability of 
routine screening of postnatal women using the Edinburgh Postnatal Depression Scale. 
Br J Gen Pract 2003;53:614-9. 
57. Mauthner NS. Postnatal depression: how can midwives help? Midwifery 
1997;13:163-71. 
58. Henshaw EJ, Flynn HA, Himle JA, O'Mahen HA, Forman J, Fedock G. Patient 
preferences for clinician interactional style in treatment of perinatal depression. Qual 
Health Res 2011;21:936-51. 
59. Goodman JH. Women's attitudes, preferences, and perceived barriers to 
treatment for perinatal depression. Birth 2009;36:60-9. 
60. Reay R, Matthey S, Ellwood D, Scott M. Long-term outcomes of participants in a 
perinatal depression early detection program. J Affect Disord 2011;129:94-103. 
61. Letourneau N, Duffett-Leger L, Stewart M, et al. Canadian mothers' perceived 
support needs during postpartum depression. J Obstet Gynecol Neonatal Nurs 
2007;36:441-9. 
62. Slade P, Morrell CJ, Rigby A, Ricci K, Spittlehouse J, Brugha TS. Postnatal 
women's experiences of management of depressive symptoms: a qualitative study. Br J 
Gen Pract 2010;60:e440-8. 
63. Woolhouse H, Brown S, Krastev A, Perlen S, Gunn J. Seeking help for anxiety 
and depression after childbirth: results of the Maternal Health Study. Arch Womens 
Ment Health 2009;12:75-83. 
64. Bennett IM, Palmer S, Marcus S, et al. "One end has nothing to do with the 
other:" patient attitudes regarding help seeking intention for depression in gynecologic 
and obstetric settings. Arch Womens Ment Health 2009;12:301-8. 
65. Wood AF, Thomas SP, Droppleman PG, Meighan M. The downward spiral of 
postpartum depression. MCN Am J Matern Child Nurs 1997;22:308-16; quiz 17. 
66. Edge D. 'It's leaflet, leaflet, leaflet then, "see you later"': black Caribbean 
women's perceptions of perinatal mental health care. Br J Gen Pract 2011;61:256-62. 
67. Mitchell AJ, Coyne J. Screening for postnatal depression: barriers to success. 
BJOG 2009;116:11-4. 
  
 
lii 
68. Byatt N, Biebel K, Debourdes-Jackson G, et al. Community Mental Health 
Provider Reluctance to Provide Pharmacotherapy May Be a Barrier to Addressing 
Perinatal Depression: A Preliminary Study. Psychiatric Quarterly 2012 ePub ahead of 
print DOI: 10.1007/s11126-012-9236-0. 
69. Woltmann E, Grogan-Kaylor A, Perron B, Georges H, Kilbourne AM, Bauer MS. 
Comparative effectiveness of collaborative chronic care models for mental health 
conditions across primary, specialty, and behavioral health care settings: systematic 
review and meta-analysis. The American journal of psychiatry 2012;169:790-804. 
70. Melville JL, Reed SD, Russo J, et al. Improving care for depression in obstetrics 
and gynecology: a randomized controlled trial. Obstet Gynecol 2014;123:1237-46. 
71. Leung SS, Leung C, Lam TH, et al. Outcome of a postnatal depression screening 
programme using the Edinburgh Postnatal Depression Scale: a randomized controlled 
trial. J Public Health (Oxf) 2011;33:292-301. 
72. LaRocco-Cockburn A, Reed SD, Melville J, et al. Improving depression treatment 
for women: integrating a collaborative care depression intervention into OB-GYN care. 
Contemp Clin Trials 2013;36:362-70. 
73. Grote NK, Katon WJ, Lohr MJ, et al. Culturally relevant treatment services for 
perinatal depression in socio-economically disadvantaged women: the design of the 
MOMCare study. Contemp Clin Trials 2014;39:34-49. 
74. Yawn BP, Dietrich AJ, Wollan P, et al. TRIPPD: a practice-based network 
effectiveness study of postpartum depression screening and management. Ann Fam 
Med 2012;10:320-9. 
75. Bachman J, Pincus HA, Houtsinger JK, Unutzer J. Funding mechanisms for 
depression care management: opportunities and challenges. Gen Hosp Psychiatry 
2006;28:278-88. 
76. Eisenberg JM, Power EJ. Transforming insurance coverage into quality health 
care: voltage drops from potential to delivered quality. JAMA : the journal of the 
American Medical Association 2000;284:2100-7. 
77. Connor DF, McLaughlin TJ, Jeffers-Terry M, et al. Targeted child psychiatric 
services: a new model of pediatric primary clinician--child psychiatry collaborative care. 
Clin Pediatr (Phila) 2006;45:423-34. 
78. Sarvet B, Gold J, Bostic JQ, et al. Improving access to mental health care for 
children: the Massachusetts Child Psychiatry Access Project. Pediatrics 2010;126:1191-
200. 
79. Straus JH, Sarvet B. Behavioral health care for children: the massachusetts child 
psychiatry access project. Health Aff (Millwood) 2014;33:2153-61. 
80. Hajduk AM, Lemon SC, McManus DD, et al. Cognitive impairment and self-care 
in heart failure. Clin Epidemiol 2013;5:407-16. 
81. Chinman M, Early D, Ebener P, et al. Getting To Outcomes: a community-based 
participatory approach to preventive interventions. J Interprof Care 2004;18:441-3. 
82. Toussaint JS, Berry LL. The promise of Lean in health care. Mayo Clin Proc 
2013;88:74-82. 
83. Rycroft-Malone J. The PARIHS framework--a framework for guiding the 
implementation of evidence-based practice. J Nurs Care Qua2004;19:297-304. 
84. Perla RJ, Provost LP, Parry GJ. Seven propositions of the science of 
improvement: exploring foundations. Qual Manag Health Care 2013;22:170-86. 
  
 
liii 
85. Wagner EH. Chronic disease management: what will it take to improve care for 
chronic illness? Eff Clin Pract 1998;1:2-4. 
86. Wagner EH, Austin BT, Davis C, Hindmarsh M, Schaefer J, Bonomi A. Improving 
chronic illness care: translating evidence into action. Health Aff (Millwood) 2001;20:64-
78. 
87. Wagner EH, Austin BT, Von Korff M. Organizing care for patients with chronic 
illness. The Milbank quarterly 1996;74:511-44. 
88. Renders CM, Valk GD, Griffin S, Wagner EH, Eijk JT, Assendelft WJ. 
Interventions to improve the management of diabetes mellitus in primary care, 
outpatient and community settings. Cochrane database of systematic reviews 
2001:CD001481. 
89. Weinreb L, Byatt N, Moore Simas TA, Tenner K, Savageau JA. What happens to 
mental health treatment during pregnancy? Women's experience with prescribing 
providers. Psychiatr Q 2014;85:349-55. 
90. Guydish J, Ziedonis D, Tajima B, et al. Addressing Tobacco Through 
Organizational Change (ATTOC) in residential addiction treatment settings. Drug 
Alcohol Depend 2012;121:30-7. 
91. Ziedonis DM, Zammarelli L, Seward G, et al. Addressing tobacco use through 
organizational change: a case study of an addiction treatment organization. J 
Psychoactive Drugs 2007;39:451-9. 
92. Lin MF, Moyle W, Chang HJ, Chou MH, Hsu MC. Effect of an Interactive 
Computerized Psycho-education System on patients suffering from depression. J Clin 
Nurs 2008;17:667-76. 
93. Dowrick C, Dunn G, Ayuso-Mateos JL, et al. Problem solving treatment and 
group psychoeducation for depression: multicentre randomised controlled trial. 
Outcomes of Depression International Network (ODIN) Group. BMJ 2000;321:1450-4. 
94. Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. 
Development of the 10-item Edinburgh Postnatal Depression Scale. British Journal of 
Psychiatry 1987;150:782-6. 
95. Chen H, Wang J, Ch'ng YC, Mingoo R, Lee T, Ong J. Identifying mothers with 
postpartum depression early: integrating perinatal mental health care into the obstetric 
setting. ISRN Obstet Gynecol 2011;2011:309189. 
96. Flynn HA, O'Mahen HA, Massey L, Marcus S. The impact of a brief obstetrics 
clinic-based intervention on treatment use for perinatal depression. J Womens Health 
(Larchmt) 2006;15:1195-204. 
97. Burton A, Patel S, Kaminsky L, et al. Depression in pregnancy: time of screening 
and access to psychiatric care. J Matern Fetal Neonatal Med 2011;24:1321-4. 
98. Goodman JH, Tyer-Viola L. Detection, treatment, and referral of perinatal 
depression and anxiety by obstetrical providers. J Womens Health (Larchmt) 
2010;19:477-90. 
99. Glavin K, Smith L, Sorum R, Ellefsen B. Redesigned community postpartum care 
to prevent and treat postpartum depression in women--a one-year follow-up study. J 
Clin Nurs 2010;19:3051-62. 
100. Glavin K, Smith L, Sorum R. Prevalence of postpartum depression in two 
municipalities in Norway. Scand J Caring Sci 2009;23:705-10. 
  
 
liv 
101. Chaudron LH, Kitzman HJ, Peifer KL, Morrow S, Perez LM, Newman MC. 
Prevalence of maternal depressive symptoms in low-income Hispanic women. J Clin 
Psychiatry 2005;66:418-23. 
102. Byatt N BK, Debourdes-Jackson G, Lundquist R, Moore Simas T, Ziedonis D, 
Allison J. Overcoming the Barriers to Perinatal Mental Health Treatment:  Perspective of 
Postpartum Women In; 2011 (in preparation). 
103. Flynn HA, Henshaw E, O'Mahen H, Forman J. Patient perspectives on improving 
the depression referral processes in obstetrics settings: a qualitative study. Gen Hosp 
Psychiatry 2010;32:9-16. 
104. Rothera I OM. Managing perinatal mental health disorders effectively: identifying 
the neccessary components of service provision and delivery. Psychiatric Bulletin 
2008;32:131-3. 
105. Miller L, Shade M, Vasireddy V. Beyond screening: assessment of perinatal 
depression in a perinatal care setting. Arch Womens Ment Health 2009;12:329-34. 
106. Miller LJ, McGlynn A, Suberlak K, Rubin LH, Miller M, Pirec V. Now what? 
Effects of on-site assessment on treatment entry after perinatal depression screening. J 
Womens Health (Larchmt) 2012;21:1046-52. 
107. Harvey ST, Fisher LJ, Green VM. Evaluating the clinical efficacy of a primary 
care-focused, nurse-led, consultation liaison model for perinatal mental health. Int J 
Ment Health Nurs 2012;21:75-81. 
108. Scholle SH, Haskett RF, Hanusa BH, Pincus HA, Kupfer DJ. Addressing 
depression in obstetrics/gynecology practice. General Hospital Psychiatry 2003;25:83-
90. 
109. Leon AC, Davis LL, Kraemer HC. The role and interpretation of pilot studies in 
clinical research. J Psychiatr Res 2011;45:626-9. 
110. Delatte R, Cao H, Meltzer-Brody S, Menard MK. Universal screening for 
postpartum depression: an inquiry into provider attitudes and practice. Am J Obstet 
Gynecol 2009;200:e63-4. 
111. Regional Teams Enhance Ability of Primary Care Clinicians Throughout 
Massachusetts to Serve Children and Adolescents With Mental Health Issues. 2011. 
(Accessed March 11, 2013, 2013, at http://innovations.ahrq.gov/content.aspx?id=3058.) 
 
 
